Qiagen and Celera establish distribution agreement for respiratory pathogen panel
Qiagen and Celera have announced an agreement under which Qiagen will distribute a Celera molecular multiplex assay. The assay is the next generation version of Qiagen’s ResPlex II assay for detection of respiratory pathogens. Multiplex assays allow testing for a multiple number of different pathogens in a single run.
Under the terms of the agreement, Qiagen has the exclusive worldwide rights to distribute this multiplex test kit, which will be manufactured by Celera. The ResPlex assay detects 19 different pathogens associated with respiratory infections and is designed for use with LiquiChip (Luminex) 100 and 200 instrument platforms.
The new ResPlex kits will be available through Qiagen’s existing sales channels. The new test will be submitted for regulatory approval in the United States and Europe.
Jian Zhou Medal recognises anaesthesia, blood pressure research
The Australian Academy of Health and Medical Sciences has announced Professor Britta Regli-von...
Australian among 2025 Nobel Prize winners
The first of the 2025 Nobel Prizes have been announced — and this year's awards...
ATSE elects its next President, 2025 Fellows
The Australian Academy of Technological Sciences and Engineering (ATSE) has elected 35 new...
